Status:
COMPLETED
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Skin Reactions Secondary to Radiation Therapy
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the percent change in women who experience grade 3 or 4 radiation dermatitis as defined by the Stanford Radiation Dermatitis Scoring System during radiation treatm...
Eligibility Criteria
Inclusion
- Women with breast cancer who plan to undergo radiation therapy to the breast or chest wall
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Women with scleroderma or discoid lupus
- Women with inflammatory breast cancer as evidenced by clinical assessment
- Women with breast cancer involving the skin
- Women who have undergone prior radiotherapy to the chest wall and/or breast
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2016
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02203565
Start Date
July 1 2014
End Date
July 7 2016
Last Update
July 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University, School of Medicine
Stanford, California, United States, 94305